Management of HCV with Viral Load of 370 IU/mL
Treatment is absolutely indicated for this patient with detectable HCV RNA of 370 IU/mL, as any detectable viral load confirms active chronic hepatitis C infection requiring antiviral therapy.
Confirmation of Active Infection
A viral load of 370 IU/mL definitively confirms active HCV infection requiring treatment. While this is a relatively low viral load, any detectable HCV RNA indicates viral replication and warrants direct-acting antiviral (DAA) therapy 1. The specific viral load level does not contraindicate treatment or alter the fundamental indication for therapy.
Essential Pre-Treatment Evaluation
Before initiating treatment, you must determine:
- HCV genotype (if not already known) - this guides specific regimen selection, though pangenotypic regimens eliminate this requirement for treatment-naive patients 1
- Presence or absence of cirrhosis - use noninvasive markers (FIB-4, APRI, elastography) rather than biopsy 1
- Treatment history - treatment-naive vs. treatment-experienced status affects regimen choice and duration
- Baseline laboratory tests within 12 weeks: complete blood count, INR, hepatic function panel, creatinine/eGFR, HCV RNA quantification 2
- Drug-drug interactions with current medications 2
Treatment Recommendations by Genotype
For Genotype 1a (Treatment-Naive, No Cirrhosis):
Ledipasvir/sofosbuvir 90/400 mg daily for 12 weeks (can shorten to 8 weeks if baseline HCV RNA <6,000 IU/mL, which this patient meets) 3
Alternative options:
For Genotype 1a (Treatment-Naive, With Cirrhosis):
Ledipasvir/sofosbuvir 90/400 mg daily for 12 weeks 3
- Glecaprevir/pibrentasvir for 12 weeks 3
For Genotype 1b (Treatment-Naive, No Cirrhosis):
Ledipasvir/sofosbuvir 90/400 mg daily for 12 weeks 3
- Glecaprevir/pibrentasvir for 8 weeks 3
For Genotype 2 (Treatment-Naive):
Sofosbuvir 400 mg + weight-based ribavirin for 12 weeks (extend to 16 weeks if cirrhosis) 2
For Genotype 3 (Treatment-Naive, No Cirrhosis):
Glecaprevir/pibrentasvir for 8 weeks 3
- Sofosbuvir/velpatasvir for 12 weeks 3
For Genotype 3 (Treatment-Naive, With Cirrhosis):
Sofosbuvir/velpatasvir + ribavirin for 12 weeks 3
- Glecaprevir/pibrentasvir for 12 weeks 3
For Genotype 4 (Treatment-Naive):
Ledipasvir/sofosbuvir for 12 weeks 3
- Glecaprevir/pibrentasvir for 8 weeks (no cirrhosis) or 12 weeks (cirrhosis) 3
- Sofosbuvir/velpatasvir for 12 weeks 3
Critical Considerations for Low Viral Load
The low viral load of 370 IU/mL actually favors excellent treatment outcomes. Lower baseline viral loads are associated with higher sustained virological response (SVR) rates across all DAA regimens 4. This patient would likely qualify for shortened treatment duration with certain regimens (8 weeks with ledipasvir/sofosbuvir if genotype 1a without cirrhosis and HCV RNA <6,000 IU/mL) 3.
Common Pitfalls to Avoid
- Do not delay treatment waiting for viral load to increase - any detectable HCV RNA warrants immediate treatment consideration
- Do not assume low viral load means mild disease - assess fibrosis stage independently, as viral load does not correlate with liver damage severity 5
- Verify the viral load result if there's clinical suspicion of false positive, but 370 IU/mL is well above most assay detection limits and represents true viremia
- Assess for renal impairment before selecting sofosbuvir-based regimens in patients with eGFR <30 mL/min/1.73m² - glecaprevir/pibrentasvir is preferred in severe CKD 6
Expected Outcomes
With modern pangenotypic DAA regimens, SVR rates exceed 95-99% across all genotypes in treatment-naive patients without cirrhosis 3, 1. The low baseline viral load in this patient predicts excellent treatment response.